---
title: 'Funding Daily Summary: What Happened on November 14, 2026'
headline: Windward raises $225 million in IPO and Sanofi private placement
description: PhaSER received a renewed Gates Foundation grant, while Rezera postponed
  its planned offering.
url: https://thebench.bio/news/funding/2026-11-14
topic: funding
date: '2026-11-14'
covers:
- '2026-11-14'
date_published: '2026-11-14T12:01:03Z'
date_modified: '2026-11-15T00:00:47Z'
tags:
- Funding
- Industry
- Research
sources: 4
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on November 14, 2026

**Windward raises $225 million in IPO and Sanofi private placement**

PhaSER received a renewed Gates Foundation grant, while Rezera postponed its planned offering.

## Today in brief

Windward Bio Group raised $225 million through an IPO and a separate investment from Sanofi. [1] [2] The money will fund two respiratory and immunology programs, with data expected in 2027 and pivotal asthma results expected in 2029. [2] [3]

## Windward raises $225 million for two antibody programs

Windward priced about 10.3 million IPO shares at $17 each, raising $175 million, and secured another $50 million from Sanofi in a private placement. [2] [3] The offering was priced at the midpoint of its proposed range, and Windward shares rose 68% in after-hours trading Friday. [1] [2]

The proceeds will mainly support WIN378, an antibody targeting TSLP that is being tested for severe asthma and chronic obstructive pulmonary disease, and WIN027, which blocks TSLP and IL-13. [2] [3] Windward expects asthma and COPD data for WIN378 and early results for WIN027 in 2027. [2] [3] The company expects preliminary results from two pivotal asthma studies in the first half of 2029 and estimates its cash will last into that period. [2] [3]

## Also worth knowing

- PhaSER Biomedical received a two-year, $2.7 million Gates Foundation grant renewal to support neglected-disease drug research using its humanized mouse models. [4]
- Rezera postponed its planned offering amid volatile market conditions. [1] [2]

## The day in numbers

- **$225 million**: Windward's combined IPO and Sanofi private-placement financing [2] [3]
- **2029**: Windward's expected timing for preliminary results from two pivotal asthma studies [2] [3]
- **$2.7 million**: PhaSER's renewed Gates Foundation grant for two years of research [4]

## Also published

- [Windward Bio catches $175m from its IPO](<https://pharmaphorum.com/news/windward-bio-catches-175m-its-ipo>), pharmaphorum
- [Windward prices $175M IPO to advance China-licensed lung drugs](<https://www.biopharmadive.com/news/windward-ipo-pricing-immune-drugs-china-deals-tezspire/874533/>), BioPharma Dive

## Sources

1. [Windward prices IPO, Rezera postpones its offering: Finance Report](<https://www.biocentury.com/article/661604/windward-prices-ipo-rezera-postpones-its-offering-finance-report?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-14
2. [Windward raises $175M in IPO, adds $50M from Sanofi](<https://european-biotechnology.com/latest-news/windward-raises-175m-in-ipo-adds-50m-from-sanofi/>), European Biotechnology, 2026-11-13
3. [Windward Bio’s Stock Market Debut Reels In $225M for Better Biologic Drugs](<https://medcitynews.com/2026/11/windward-bio-ipo-long-acting-antibody-tslp-asthma-copd-atopic-dermatitis-wwb/>), MedCity News, 2026-11-13
4. [PhaSER secures $2.7m Gates Foundation renewal for neglected disease drug research](<https://pharmafile.com/news/phaser-secures-2-7m-gates-foundation-renewal-for-neglected-disease-drug-research/>), Pharmafile, 2026-11-14

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661604/windward-prices-ipo-rezera-postpones-its-offering-finance-report?utm_source=bc_rss&utm_medium=rss>
[2]: <https://european-biotechnology.com/latest-news/windward-raises-175m-in-ipo-adds-50m-from-sanofi/>
[3]: <https://medcitynews.com/2026/11/windward-bio-ipo-long-acting-antibody-tslp-asthma-copd-atopic-dermatitis-wwb/>
[4]: <https://pharmafile.com/news/phaser-secures-2-7m-gates-foundation-renewal-for-neglected-disease-drug-research/>
